Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M, Provencio M, Nadal E, Insa A, Del Rosario García-Campelo M, Lázaro-Quintela M, Dómine M, Majem M, Rodriguez-Abreu D, Martinez-Marti A, De Castro Carpeño J, Cobo M, López Vivanco G, Del Barco E, Bernabé R, Viñolas N, Barneto Aranda I, Massuti B, Sierra-Rodero B, Martinez-Toledo C, Fernández-Miranda I, Serna-Blanco R, Romero A, Calvo V, Cruz-Bermúdez A.
Casarrubios M, et al.
J Immunother Cancer. 2022 Sep;10(9):e005320. doi: 10.1136/jitc-2022-005320.
J Immunother Cancer. 2022.
PMID: 36171009
Free PMC article.
Clinical Trial.
Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment analysis. ...A greater effect of neoadjuvant therapy was also seen in CPR tumors with a reduction of tumor markers and IFNgamma signaling a …
Differential-expressed genes between groups and pathway enrichment analysis were assessed using DESeq2 and gene set enrichment …